AZ/Merck’s Lynparza approved by SMC to treat advanced prostate cancer in Scotland
Up to 20% of prostate cancer cases are classified as castration-resistant
Read More
Tag: Lynparza
NICE nod for AstraZeneca’s Lynparza
Therapy treats patients with specific types of ovarian, fallopian tube or primary peritoneal cancer
Read More
AstraZeneca and MSD’s Lynparza gets green light
Combination therapy treat patients with metastatic castration-resistant prostate cancer
Read More
Lynparza in combination with abiraterone granted priority review in US
New therapy is aimed at patients with metastatic castration-resistant prostate cancer
Read More
Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
Read More
NICE approves Lynparza plus Avastin via Cancer Drugs Fund
Genomic HRD testing to be launched to support the introduction of this treatment regimen
Read More
NICE rejects AZ’s Lynparza for metastatic prostate cancer
Appraisal committee highlighted uncertainties in the clinical evidence for PARP inhibitor
Read More
Lynparza scores two new EU approvals
PARP inhibitor approved for new ovarian and prostate cancer indications
Read More
GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval
Both PARP inhibitors receive positive opinions from CHMP
Read More
Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer
Detailed results presented at ESMO also show benefit in prostate cancer
Read More
ICR study combines precision medicines to treat drug-resistant cancers
Researchers found combination treatment showed promise against a range of cancer types
Read More
EU nod for Lynparza in pancreatic cancer
The drug is the only PARP inhibitor approved in this disease
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
